We are live on ! Find out more
MG

Michael Gelband ExodusPoint Capital Management

AUM $15.5B
1-Year Est. Return 38.81%
 

Michael Gelband is a co-founder of ExodusPoint Capital Management, a multi-strategy hedge fund launched by veterans of larger alternative platforms. The firm pursues diversified strategies across asset classes with a focus on risk-managed absolute returns. Gelband’s firm is followed as part of the newer generation of multi-strategy complexes.

This Fund
S&P 500
This Quarter Est. Return
+7.87%
1 Year Est. Return
+38.81%
3 Year Est. Return
+110.53%
5 Year Est. Return
+124.16%
10 Year Est. Return
–
AUM
$9.04B
AUM Growth
+$2.19B
Cap. Flow
+$1.88B
Cap. Flow %
20.78%
Top 10 Hldgs %
34.88%
Holding
3,092
New
1,032
Increased
581
Reduced
587
Closed
820

Top Buys

Rank Stock Value
1
MSFT icon
Microsoft
MSFT
+$435M
2
AMZN icon
Amazon
AMZN
+$334M
3
MRNA icon
Moderna
MRNA
+$53.9M
4
LIN icon
Linde
LIN
+$44.2M
5
DTE icon
DTE Energy
DTE
+$43.5M

Top Sells

Rank Stock Value
1
IWD icon
iShares Russell 1000 Value ETF
IWD
+$63.6M
2
CMCSA icon
Comcast
CMCSA
+$39.7M
3
EVRG icon
Evergy
EVRG
+$38.5M
4
PEG icon
Public Service Enterprise Group
PEG
+$38.4M
5
TECH icon
Bio-Techne
TECH
+$30.9M

Sector Composition

Rank Sector Weight
1 Technology 15.37%
2 Consumer Discretionary 10.36%
3 Financials 7.14%
4 Industrials 6.8%
5 Healthcare 6.46%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ASC icon
2226
Ardmore Shipping
ASC
$746M
$45K ﹤0.01%
+10,733
New +$45.9K
PAYS icon
2227
Paysign
PAYS
$771M
$45K ﹤0.01%
+14,283
New +$51.3K
TXMD icon
2228
TherapeuticsMD
TXMD
$24M
$45K ﹤0.01%
751
-686
-48% -$41.6K
TTOO
2229
DELISTED
T2 Biosystems, Inc
TTOO
$45K ﹤0.01%
8
-33
-80% -$213K
HEPA
2230
DELISTED
Hepion Pharmaceuticals
HEPA
$44K ﹤0.01%
+22
New +$40.3K
VSTM icon
2231
Verastem
VSTM
$621M
$44K ﹤0.01%
907
-2,575
-74% -$107K
NPKI
2232
NPK International
NPKI
$1.12B
$44K ﹤0.01%
12,759
-3,335
-21% -$11.3K
FBIO icon
2233
Fortress Biotech
FBIO
$97.7M
$43K ﹤0.01%
+812
New +$49K
ALNA
2234
DELISTED
Allena Pharmaceuticals
ALNA
$43K ﹤0.01%
33,413
-6,300
-16% -$7.63K
LJPC
2235
DELISTED
La Jolla Pharmaceutical Company
LJPC
$43K ﹤0.01%
10,073
-1,514
-13% -$6.49K
RMTI icon
2236
Rockwell Medical
RMTI
$31.8M
$42K ﹤0.01%
418
+32
+8% +$3.3K
ENZ
2237
DELISTED
Enzo Biochem, Inc.
ENZ
$42K ﹤0.01%
+13,166
New +$41.4K
REFR icon
2238
Research Frontiers
REFR
$16.3M
$41K ﹤0.01%
+17,451
New +$43.5K
PARAA
2239
DELISTED
Paramount Global Class A
PARAA
$36K ﹤0.01%
749
-1,954
-72% -$89K
RVLP
2240
DELISTED
RVL Pharmaceuticals plc Ordinary Shares
RVLP
$36K ﹤0.01%
+12,077
New +$37K
CHGA
2241
Change Agents Corp
CHGA
$3.48M
$35K ﹤0.01%
+240
New +$38.3K
QUAD icon
2242
Quad
QUAD
$528M
$35K ﹤0.01%
8,379
-4,955
-37% -$18K
WATT icon
2243
Energous
WATT
$64.1M
$35K ﹤0.01%
20
-71
-78% -$129K
NBEV
2244
DELISTED
NewAge, Inc. Common Stock (Delaware)
NBEV
$34K ﹤0.01%
+15,399
New +$35.9K
CEMI
2245
DELISTED
Chembio diagnostics, Inc.
CEMI
$32K ﹤0.01%
+10,672
New +$37.2K
STGW icon
2246
Stagwell
STGW
$2.17B
$29K ﹤0.01%
5,041
-86,732
-95% -$405K
RNTX
2247
Rein Therapeutics
RNTX
$69M
$29K ﹤0.01%
+1,155
New +$28.8K
OPGN
2248
DELISTED
OpGen, Inc
OPGN
$28K ﹤0.01%
+61
New +$27.9K
SREV
2249
DELISTED
ServiceSource International, Inc.
SREV
$28K ﹤0.01%
+19,894
New +$26.2K
MLSS icon
2250
Milestone Scientific
MLSS
$42M
$27K ﹤0.01%
+11,052
New +$26.8K
88 89
90
91 92

Similar funds

FGP
Freestone Grove Partners San Francisco, California $15.6B AUM 27.39% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $15.7B AUM 36.4% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Impax Asset Management Group
Impax Asset Management Group London, United Kingdom $15.4B AUM 26.43% 1-Year Est. Return
AA
Acorns Advisers Irvine, California $15.3B AUM 18.32% 1-Year Est. Return
OTPPB
Ontario Teachers' Pension Plan Board Toronto, Ontario, Canada $15.8B AUM 1.29% 1-Year Est. Return
NMIFOAC
National Mutual Insurance Federation of Agricultural Cooperatives Tokyo, Japan, Japan $15.3B AUM 24.71% 1-Year Est. Return

Michael Gelband's Q2 2021 Portfolio in Review

As of Q2 2021, Michael Gelband held 3,092 positions worth $9.04B, up 32% from $6.86B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Michael Gelband deployed $1.88B of net new capital in Q2 2021, opening 1,032 new positions and adding to 581 existing holdings. Its largest new stake was Linde: 151,692 shares worth $43.9M.

By sector, the portfolio is most concentrated in Technology at 15% of assets, up from 13% a quarter earlier, followed by Consumer Discretionary and Financials.

On the sell side, the largest reduction was iShares Russell 1000 Value ETF, an estimated $63.6M trimmed.

  • Michael Gelband's largest Q2 2021 buy was Linde: 151,692 shares worth $43.9M.
  • Michael Gelband added most to Microsoft in Q2 2021, an estimated $435M increase.
  • Michael Gelband's biggest Q2 2021 reduction was iShares Russell 1000 Value ETF, cutting an estimated $63.6M.
  • Michael Gelband fully exited Charles River Laboratories in Q2 2021, selling an estimated $27.9M.
  • Michael Gelband's ten largest holdings make up 35% of its $9.04B portfolio in Q2 2021.
  • Michael Gelband opened 1,032 new positions and closed 820 in Q2 2021.
  • Michael Gelband's portfolio value rose 32% quarter-over-quarter to $9.04B.

Based on ExodusPoint Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.